These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21299465)

  • 1. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.
    D'Arena G; Gobbi PG; Broglia C; Sacchi S; Quarta G; Baldini L; Iannitto E; Falcone A; Guariglia R; Pietrantuono G; Villani O; Martorelli MC; Mansueto G; Sanpaolo G; Cascavilla N; Musto P; ; ;
    Leuk Lymphoma; 2011 May; 52(5):771-5. PubMed ID: 21299465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
    Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
    Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
    Gimsing P; Carlson K; Turesson I; Fayers P; Waage A; Vangsted A; Mylin A; Gluud C; Juliusson G; Gregersen H; Hjorth-Hansen H; Nesthus I; Dahl IM; Westin J; Nielsen JL; Knudsen LM; Ahlberg L; Hjorth M; Abildgaard N; Andersen NF; Linder O; Wisløff F
    Lancet Oncol; 2010 Oct; 11(10):973-82. PubMed ID: 20863761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial.
    Musto P; Falcone A; Sanpaolo G; Bodenizza C; Cascavilla N; Melillo L; Scalzulli PR; Dell'Olio M; La Sala A; Mantuano S; Nobile M; Carella AM
    Leuk Lymphoma; 2003 Sep; 44(9):1545-8. PubMed ID: 14565658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
    Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs M; Blacklock H; Bell R; Simeone JF; Reitsma DJ; Heffernan M; Seaman J; Knight RD
    J Clin Oncol; 1998 Feb; 16(2):593-602. PubMed ID: 9469347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.
    García-Sanz R; Oriol A; Moreno MJ; de la Rubia J; Payer AR; Hernández MT; Palomera L; Teruel AI; Blanchard MJ; Gironella M; Ribas P; Bargay J; Abellá E; Granell M; Ocio EM; Ribera JM; San Miguel JF; Mateos MV;
    Haematologica; 2015 Sep; 100(9):1207-13. PubMed ID: 26069291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.
    Sanfilippo KM; Gage B; Luo S; Weilbaecher K; Tomasson M; Vij R; Colditz G; Carson K
    Leuk Lymphoma; 2015 Mar; 56(3):615-21. PubMed ID: 24844358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
    Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
    N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
    Brincker H; Westin J; Abildgaard N; Gimsing P; Turesson I; Hedenus M; Ford J; Kandra A
    Br J Haematol; 1998 May; 101(2):280-6. PubMed ID: 9609523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.
    Terpos E; Palermos J; Viniou N; Vaiopoulos G; Meletis J; Yataganas X
    Calcif Tissue Int; 2001 May; 68(5):285-90. PubMed ID: 11683535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous pamidronate for myeloma bone disease: can the dose be lowered?
    Terpos E; Dimopoulos MA
    Lancet Oncol; 2010 Oct; 11(10):913-4. PubMed ID: 20863760
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma.
    Abildgaard N; Rungby J; Glerup H; Brixen K; Kassem M; Brincker H; Heickendorff L; Eriksen EF; Nielsen JL
    Eur J Haematol; 1998 Aug; 61(2):128-34. PubMed ID: 9714526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates in multiple myeloma.
    Djulbegovic B; Wheatley K; Ross J; Clark O; Bos G; Goldschmidt H; Cremer F; Alsina M; Glasmacher A
    Cochrane Database Syst Rev; 2001; (4):CD003188. PubMed ID: 11687178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.
    Martín A; García-Sanz R; Hernández J; Bladé J; Suquía B; Fernández-Calvo J; González M; Mateo G; Orfao A; San Miguel JF
    Br J Haematol; 2002 Jul; 118(1):239-42. PubMed ID: 12100153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
    Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
    Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.